Risankizumab will be administered as intravenous (IV) or subcutaneous (SC) injection.
Other Name: ABBV-066
Other Name: BI 655066
ABBVIE CALL CENTER
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.